{
    "clinical_study": {
        "@rank": "168006", 
        "arm_group": [
            {
                "arm_group_label": "Econazole Nitrate Foam", 
                "arm_group_type": "Experimental", 
                "description": "Investigational Drug Product"
            }, 
            {
                "arm_group_label": "Vehicle Foam", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Vehicle Foam Comparator"
            }, 
            {
                "arm_group_label": "Econazole Nitrate Cream", 
                "arm_group_type": "Active Comparator", 
                "description": "Active comparator cream product"
            }
        ], 
        "brief_summary": {
            "textblock": "To compare the pharmacokinetics of Econazole Nitrate  Foam with Econazole Nitrate  Cream in\n      subjects with interdigital tinea pedis aged 12 years to less than 18 years."
        }, 
        "brief_title": "Comparative PK Study of Econazole Nitrate Foam and Econazole Nitrate Cream in Subjects With Interdigital Tinea Pedis Aged 12 Years to Less Than 18 Years", 
        "completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "condition": "Interdigital Tinea Pedis", 
        "condition_browse": {
            "mesh_term": [
                "Tinea", 
                "Tinea Pedis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Based on the results of a previous clinical study evaluating the pharmacokinetics, safety\n      and efficacy of EN Foam  versus the reference listed  econazole nitrate cream and the foam\n      vehicle in adults, the current clinical study is being conducted to provide additional\n      pharmacokinetic data for EN  in the foam formulation in subjects ages 12 to less than 18\n      years with interdigital tinea pedis to support a clinical bridge for systemic safety to the\n      RLD in this pediatric population. The study also includes clinical and safety endpoints."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Be between 12 years and less than 18 years of age and of either sex.\n\n          -  Have a clinical diagnosis of interdigital tinea pedis\n\n          -  Parent/guardian has provided written informed consent and the subject has provided\n             written assent.\n\n          -  Be willing and able to use the assigned study medication as directed and to commit to\n             all follow-up visits for the duration of the study.\n\n          -  Have microscopic evidence (positive KOH) of the presence of fungi and a positive\n             fungal culture.\n\n          -  Be in good health and free of any disease or physical condition which might, in the\n             Investigator's opinion, expose the subject to an unacceptable risk by study\n             participation.\n\n          -  Females must be non-pregnant, non-lactating and not intending to become pregnant\n             during the course of the study.\n\n        Exclusion Criteria:\n\n          -  Is pregnant, nursing or planning a pregnancy during the study\n\n          -  Has used topical antifungals or topical corticosteroids on the feet within 14 days\n             prior to the start of the study.\n\n          -  Has received systemic antifungal therapy within 12 weeks prior to the start of the\n             study medication.\n\n          -  Has used systemic antibacterials or systemic corticosteroids within 14 days prior to\n             the start of the study.\n\n          -  Has a history of uncontrolled diabetes mellitus or is immunocompromised (due to\n             disease, e.g., HIV, or medications).\n\n          -  Has concurrent moccasin-type tinea pedis (in the opinion of the Investigator).\n\n          -  Has any other skin disease which might interfere with the evaluation of tinea pedis.\n\n          -  Is currently enrolled in an investigational drug or device study.\n\n          -  Has received an investigational drug or treatment with an investigational device\n             within 30 days prior to entering this study.\n\n          -  Is unreliable, including subjects with a history of drug or alcohol abuse.\n\n          -  Has known hypersensitivity to any of the components of the study medications."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "18 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01696799", 
            "org_study_id": "079-2951-109"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Econazole Nitrate Foam", 
                    "Econazole Nitrate Cream"
                ], 
                "intervention_name": "Econazole Nitrate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Vehicle Foam", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Econazole"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "September 28, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Diego", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92123"
                }, 
                "name": "Therapeutics Inc."
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Multi-Center, Randomized Comparative Study of the Pharmacokinetics of Econazole Nitrate 1% Foam and Econazole Nitrate 1% Cream in Subjects With Interdigital Tinea Pedis Aged 12 Years to Less Than 18 Years", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Blood will be taken at Baseline (Day 1) prior to the application of medication, and at the end of treatment (Day 28), just prior to the last dose of medication, and at 7 (\u00b11 hr) hours post-drug application and a third blood draw 4 (\u00b11 hr) hours after the second PK blood draw.", 
                "measure": "Plasma Levels of Econazole Nitrate", 
                "safety_issue": "No", 
                "time_frame": "28 Days"
            }, 
            {
                "description": "At the end of treatment (Day 28), the Investigator will assess the subject's response to treatment using a 5-point scale (1 = excellent, 2 = very good, 3 = good, 4 = fair, and 5 = poor).", 
                "measure": "Investigator Assessment of Response to Treatment", 
                "safety_issue": "No", 
                "time_frame": "28 Days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01696799"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Measures of study medication compliance will include the total number of applications, duration of treatment, and the total amount of study medication used. The amount of study medication used will be determined post-study following thereturn of all clinical supplies.", 
            "measure": "Dosing Compliance", 
            "safety_issue": "Yes", 
            "time_frame": "28 Days"
        }, 
        "source": "AmDerma", 
        "sponsors": {
            "collaborator": {
                "agency": "AmDerma Pharmaceuticals, LLC", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "AmDerma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}